152 results on '"Bordogna, Walter"'
Search Results
2. Characteristics and Survival Outcomes of Patients With Metastatic RET Fusion–Positive Solid Tumors Receiving Non-RET Inhibitor Standards of Care in a Real-World Setting
3. Concordance Between Tissue ALK Detection by Immunohistochemistry and Plasma ALK Detection by Next-Generation Sequencing in the Randomized Phase 3 ALEX Study in Patients With Treatment-Naive Advanced ALK-Positive NSCLC
4. Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer
5. ALK Mutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-Positive NSCLC: Pooled Analysis of Two Prospective Trials
6. Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer
7. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
8. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study
9. Pralsetinib in Patients with Advanced/metastatic RET-altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study
10. Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer
11. Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non–small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria
12. Development of a functional screening in melanocytes
13. Exposure–response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer
14. Supplementary Figure from Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non–small Cell Lung Cancer in the Global Phase III ALEX Trial
15. Supplementary Data from Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non–small Cell Lung Cancer in the Global Phase III ALEX Trial
16. Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies
17. Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells
18. Updated analysis of the efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumors.
19. Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non–small Cell Lung Cancer in the Global Phase III ALEX Trial
20. PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non–Small-Cell Lung Cancer
21. Pharmacometric analyses of alectinib to facilitate approval of the optimal dose for the first‐line treatment of anaplastic lymphoma kinase – positive non‐small cell lung cancer
22. Optimized Alectinib Dose Regimen for Treatment of Patients With ALK ‐Positive Non‐Small Cell Lung Cancer Based on Robust Pharmacometric Analyses and Clinical Evidence
23. Alpha-T: An innovative decentralized (home-based) phase 2 trial of alectinib in ALK-positive (ALK+) solid tumors in a histology-agnostic setting.
24. Updated overall survival (OS) and safety data from the randomized, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC.
25. EMX homeobox genes regulate microphthalmia and alter melanocyte biology
26. Alectinib exposure-response (ER) in ALK-inhibitor naïve ALK-positive NSCLC patients: Pooled analysis across phase III studies.
27. ALINA: A phase III study of alectinib versus chemotherapy as adjuvant therapy in patients with stage IB–IIIA anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC).
28. Circulating free DNA as a prognostic biomarker in patients with advanced ALK+ NSCLC treated with alectinib from the global phase III ALEX trial.
29. Comparative effectiveness from a single-arm trial and real-world data: alectinib versus ceritinib
30. ALKMutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-Positive NSCLC: Pooled Analysis of Two Prospective Trials
31. MA07.01 Updated Pooled Analysis of CNS Endpoints in Two Phase II Studies of Alectinib in ALK+ NSCLC
32. P3.02a-016 Pooled Efficacy and Safety Data from Two Phase II Studies (NP28673 and NP28761) of Alectinib in ALK+ Non-Small-Cell Lung Cancer (NSCLC)
33. MA07.02 Updated Efficacy and Safety Data from the Phase 2 NP28761 Study of Alectinib in ALK-Positive Non-Small-Cell Lung Cancer
34. Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non–Small-Cell Lung Cancer
35. Clinical Drug-Drug Interactions Through Cytochrome P450 3A (CYP3A) for the Selective ALK Inhibitor Alectinib
36. Pooled mutation analysis for the NP28673 and NP28761 studies of alectinib in ALK+ non-small-cell lung cancer (NSCLC).
37. Effect of alectinib on cardiac electrophysiology: Results from intensive electrocardiogram (ECG) monitoring of alectinib phase I/II pivotal studies.
38. Efficacy and safety of alectinib in ALK+ non-small-cell lung cancer (NSCLC): Pooled data from two pivotal phase II studies (NP28673 and NP28761).
39. Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study
40. Updated Efficacy and Safety Data and Impact of the EML4-ALKFusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study
41. BMET-18ASSESSING CENTRAL NERVOUS SYSTEM (CNS) RESPONSE TO ALECTINIB IN TWO PHASE II STUDIES OF PRE-TREATED ALK+ NON-SMALL CELL LUNG CANCER (NSCLC): RECIST VERSUS RANO CRITERIA
42. Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: An open-label, single-arm, global phase 2 study (NP28673).
43. Clinical Drug-Drug Interactions Through Cytochrome P450 3A (CYP3A) for the Selective ALK Inhibitor Alectinib.
44. Updated efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (fp) non-small cell lung cancer (NSCLC).
45. Clinical Validation of a PCR Assay for the Detection of EGFR Mutations in Non–Small-Cell Lung Cancer: Retrospective Testing of Specimens from the EURTAC Trial
46. Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.
47. PTPRF expression as prognostic/predictive marker for treatment with erlotinib in non-small cell lung cancer (NSCLC)?
48. O-0007 Exploratory Serum Biomarker Analyses from BO21129, a Phase II Study of Erlotinib in Second-Line Pancreatic Cancer: Potential Role of Amphiregulin?
49. Retrospective EGFR mutation testing of clinical specimens from the EURTAC trial of erlotinib in non-small cell lung cancer (NSCLC) using a novel allele-specific PCR (AS-PCR) assay.
50. Plasma Cytokine and Angiogenic Factor Profiling Identifies Markers Associated with Tumor Shrinkage in Early-Stage Non–Small Cell Lung Cancer Patients Treated with Pazopanib
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.